Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment
- 31 January 2013
- journal article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 155 (1), 89-95.e3
- https://doi.org/10.1016/j.ajo.2012.06.031
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Long‐term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age‐related macular degeneration in the EXTEND‐I studyActa Ophthalmologica, 2011
- Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategyBritish Journal of Ophthalmology, 2010
- As-Needed Treatment with Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular DegenerationEuropean Journal of Ophthalmology, 2010
- Long-Term Follow-Up After Multiple Intravitreal Bevacizumab Injections for Exudative Age-Related Macular DegenerationJournal of Ocular Pharmacology and Therapeutics, 2010
- Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional settingBritish Journal of Ophthalmology, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006